Regulatory Filings • Jun 11, 2009
Regulatory Filings
Open in ViewerOpens in native device viewer
Press Release 11 June 2009
BioGaia has signed an exclusive distribution agreement for BioGaia's Probiotic Drops with the German pharmaceutical company InfectoPharm. The product will be sold under the BioGaia brand.
"InfectoPharm has a strong position and recognition among pediatricians making them an ideal partner for our top selling BioGaia Drops, and we are now confident and eager to take on the challenging German market ", says Peter Rothschild, President, BioGaia AB.
"We have closely followed the success of the BioGaia Drops in many other European markets and see a big need for this product also for the children in Germany" says Dr. Manfred Zöller, President at InfectoPharm.
InfectoPharm is a German pharmaceutical company with a strong pediatric portfolio. The company with headquarters in Heppenheim, Germany, covers the whole area of infectious diseases, gastroenterology, dermatology and pneumology. They represent the market leaders in their particular market niches.
To learn more about INFECTOPHARM or its products please visit www.infectopharm.com.
Latest press releases from BioGaia: 2009-04-23 Annual General Meeting of BioGaia 2009-04-22 Interim report 1 January – 31 March 2009 2009-03-18 Notice to attend the Annual General Meeting of BioGaia AB
Peter Rothschild, Managing Director, telephone: +46 8 -555 293 00 Jan Annwall, Deputy Managing Director, telephone: +46 8-555 293 00
BioGaia is a biotechnology company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri (Reuteri), which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.